Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 with or without cetrelimab before radical cystectomy in muscle-invasive bladder cancer
NL-OMON54183Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in bladder cancer and transitional cell carcinoma (TCC) comparing TAR-200 + cetrelimab with cetrelimab (2 arms). Primary endpoint: Pathologic complete response. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON54183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54183.